Department of Cardiology, LAIKO General Hospital, Hypertension Excellence Centre-ESH, 17 Agiou Thoma Street, 11527, Athens, Greece.
Am J Cardiovasc Drugs. 2021 Nov;21(6):619-627. doi: 10.1007/s40256-021-00467-9. Epub 2021 Mar 23.
Chronic kidney disease (CKD) is a global health problem and is strongly associated with hypertension (HTN) and impaired quality of life. Managing HTN with agents that block the renin angiotensin aldosterone system (RAAS) remains the gold standard, however there is a misleading impression that patients with impaired renal function or those receiving hemodialysis should not be treated with RAAS inhibitors. To date, only a few data in this field are available, given that this population subset is systematically excluded from many major clinical trials. The purpose of this review was to solve the difficult equation regarding the optimal use of RAAS blockade in patients with CKD.
慢性肾脏病（CKD）是一个全球性的健康问题，与高血压（HTN）和生活质量受损密切相关。用阻断肾素-血管紧张素-醛固酮系统（RAAS）的药物来控制 HTN 仍然是金标准，然而，有一种误解认为，肾功能受损的患者或接受血液透析的患者不应使用 RAAS 抑制剂。迄今为止，由于这一人群亚组系统地被排除在许多大型临床试验之外，因此该领域仅有少量相关数据。本综述的目的是解决关于 CKD 患者 RAAS 阻断最佳应用的复杂问题。
